The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer

Authors

  • Maged Ghaly, MD Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, NY, USA
  • Emile Gogineni, DO Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, NY, USA
  • Muhammad W. Saif, MD Department of Medical Oncology, Northwell Health Cancer Institute, Lake Success, NY, USA

Keywords:

Pancreatic neoplasms, Pancreas cancer; Radiosurgery, Stereotactic, Stereotactic body radiation therapy (SBRT)

Abstract

Pancreatic cancer remains a devastating disease with dismal outcomes despite the development of novel chemotherapeutic regi
mens and radiation techniques. Stereotactic body radiation therapy (SBRT) offers an advantage both in image guidance and 
radiation dose delivery to direct ablative doses to tumors with acceptable toxicity compared to conventional techniques. Recent 
literature is clustered with data pertaining to SBRT in patients with resectable, borderline resectable and locally advanced pancre
atic tumors. We here present a summary of the current data and highlight the limitations and potential for future growth. Further 
clinical study in the form of multi-institutional trials is warranted to establish the role of SBRT in combination with new chemo
therapeutic agents as well as a non-invasive alternative to surgery

References

Heestand GM, Murphy JD, Lowy AM. Approach to patients with pancreatic cancer without detectable metastases. J Clin Oncol. 2015; 33: 1770-1778. doi: 10.1200/JCO.2014.59.7930

Pollom EL, Alagappan M, von Eyben R, et al. Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity. Int J RadiatOncol Biol Phys. 2014; 90(4): 918-925. doi: 10.1016/j.ijrobp.2014.06.066

Burris HA, Moore MJ, Andersen J, et al. Improvements line therapy for patients with advanced pancreas cancer: A rando-mized trial. J Clin Oncol. 1997; 15: 2403-2413. doi: 10.1200/ JCO.1997.15.6.2403

Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial com-paring intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemci-tabine with gemcitabine alone for results of the 2000-01 FFCD/ SFRO study. Ann Oncol. 2008; 19: 1592-1599. doi: 10.1093/an-nonc/mdn281

Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369: 1691-1703. doi: 10.1056/NEJMoa1304369

Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364: 1817-1825. doi: 10.1056/NEJMoa1011923

Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabinebased or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial. Lancet Oncol. 2013; 14: 317-326. doi: 10.1016/S1470- 2045(13)70021-4

Koong AC, Le QT, Ho A, et al. Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 1017-1021. doi: 10.1016/j. ijrobp.2003.11.004

Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiothe-rapy for unresectable adenocarcinoma of the pancreas. Cancer. 2009; 115: 665-672. doi: 10.1002/cncr.24059

Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body ra-diotherapy and gemcitabine for locally advanced pancreatic can-cer. Int J Radiat Oncol Biol Phys. 2010; 78: 735-742. doi: 10.1016/j. ijrobp.2009.08.046

Mahadevan A, Miksad R, Goldstein M, et al. Induction gem-citabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys. 2011; 81: e615-622. doi: 10.1016/j.ijrobp.2011.04.045

Chuong MD, Springett GM, Freilich JM, et al. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated. Int J Radiat Oncol Biol Phys. 2013; 86: 516-522. doi: 10.1016/j.ijrobp.2013.02.022

Herman JM, Chang DT, Goodman KA, et al. Phase 2 mul-ti-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer. 2015; 121: 1128-1137. doi: 10.1002/cncr.29161

Mellon EA, Hoffe SE, Springett GM, et al. Long-term out-comes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 2015; 54: 979-985. doi: 10.3109/0284186X.2015.1004367

Chhabra A, Kaiser A, Regine WF, Chuong MD. The expanding role of stereotactic body radiation therapyfor pancreatic cancer: A review of the literature. Transl Cancer Res. 2015; 4(6): 659-670. doi: 10.3978/j.issn.2218-676X.2015.11.01

Moningi S, Marciscano AE, Rosati LM, et al. Stereotac-tic body radiation therapy in pancreatic cancer: The new frontier. Expert Rev Anticancer Ther. 2014; 14: 1461-1475. doi: 10.1586/14737140.2014.952286

Moningi S, Dholakia AS, Raman SP, et al. The role of stereotac-tic body radiation therapy for pancreatic cancer: A single-institu-tion experience. Ann Surg Oncol. 2015; 22: 2352-2358. doi: 10.1245/ s10434-014-4274-5

Rajagopalan MS, Heron DE, Wegner RE, et al. Pathologic res-ponse with neoadjuvant chemotherapy and stereotactic body radio-therapy for borderline resectable and locallyadvanced pancreatic cancer. Radiat Oncol. 2013; 8: 254. doi: 10.1186/1748-717X-8-254

He J, Moningi S, Blair AB, et al. Surgical outcomes of patients with pancreatic cancer treated with stereotactic body radiation the-rapy. J Clin Oncol. 2015; 33: abstr 341. doi: 10.1200/jco.2015.33.3_ suppl.341

Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012; 99(8): 1036-1049. doi: 10.1002/bjs.8734

Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection inpancreatic cancer. Br J Surg. 2006; 93: 1232-1237. doi: 10.1002/bjs.5397

Menon KV, Gomez D, Smith AM, Anthoney A, Verbeke CS. Impact of margin status on survival following pancreatoduodenec-tomy for cancer: The Leeds Pathology Protocol (LEEPP). HPB (Oxford). 2009; 11: 18-24. doi: 10.1111/j.1477-2574.2008.00013.x

Esposito I, Kleeff J, Bergmann F, et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008; 15: 1651-1660. doi: 10.1245/s10434-008-9839-8

Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections forpancreatic cancer: The prognostic relevance of tu-mour involvement within 1 mm of a resection margin. Histopa-Review | Volume 3 | Number 1| Ghaly M et al thology. 2009; 55: 277-283. doi: 10.1111/j.1365-2559.2009.03376.x

Jamieson NB, Foulis AK, Oien KA, et al. Positive immobili-zation margins alone donot influence survival following pancrea-tico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg. 2010; 251: 1003-1010. doi: 10.1097/SLA.0b013e3181d77369

Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg. 2012; 99: 1036- 1049. doi: 10.1002/bjs.8734

Colbert LE, Hall WA, Nickleach D, Switchenko J, Kooby DA, Landry JC. Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base. Can-cer. 2014; 120(4): 499-506. doi: 10.1002/cncr.28530

Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine mo-notherapy in patientswith resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073): 1011-1024. doi: 10.1016/S0140-6736(16)32409-6

Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3496-3502. doi: 10.1200/JCO.2007.15.8634

Varadhachary GR, Wolff RA, Crane CH, et al. Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemo-radiation for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008; 26: 3487-3495. doi: 10.1200/JCO.2007.15.8642

Cloyd JM, Chen HC, Wang X, et al. Chemotherapy versus che-moradiation as preoperative therapy for resectable pancreatic duc-tal adenocarcinoma: A propensity score adjusted analysis. Pancreas. 2019; 48(2): 216-222. doi: 10.1097/MPA.0000000000001231

Katz MH, Wang H, Balachandran A, et al. Effect of neoad-juvant chemoradiation and surgical technique on recurrence of localizedpancreatic cancer. J Gastrointest Surg. 2012; 16: 68-78; dis-cussion 78-79. doi: 10.1007/s11605-011-1748-7

Mahajan A, Ahmed S, McAleer MF, et al. Post-operative ste-reotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017; 18: 1040-1048. doi: 10.1016/S1470- 2045(17)30414-X

Aridgides P, Bogart J. Stereotactic body radiation therapy for stage I non-small cell lung cancer. Thorac Surg Clin. 2016; 26: 261- 269. doi: 10.1016/j.thorsurg.2016.04.008

Qiu H, Moravan MJ, Milano MT, Usuki KY, Katz AW. SBRT for hepatocellular carcinoma: 8-year experience from a regional transplant center. J Gastrointest Cancer. 2018; 49(4): 463-469. doi: 10.1007/s12029-017-9990-1

Kishan AU, King CR. Stereotactic body radiotherapy for low-and intermediate-risk prostate cancer. Semin Radiat Oncol. 2017; 27: 268-278. doi: 10.1016/j.semradonc.2017.02.006

Baliga S, Kabarriti R, Ohri N, et al. Stereotactic body radiothe-rapy for recurrent head and neck cancer: A critical review. Head Neck. 2017; 39: 595-601. doi: 10.1002/hed.24633

Kim MS, Kim W, Park IH, et al. Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surge-ry. Radiat Oncol J. 2015; 33: 265-275. doi: 10.3857/roj.2015.33.4.265

Song CW, Lee YJ, Griffin RJ, et al. Indirect tumor cell death after high-dose hypofractionated irradiation: Implications for ste-reotactic body radiation therapy and stereotactic radiation surge-ry. Int J Radiat Oncol Biol Phys. 2015; 93: 166-172. doi: 10.1016/j. ijrobp.2015.05.016

Park HJ, Griffin RJ, Hui S, Levitt SH, Song CW. Radiation-in-duced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS). Radiat Res. 2012; 177: 311-327. doi: 10.1667/rr2773.1

Brown JM, Carlson DJ, Brenner DJ. The tumor radiobiology of SRS and SBRT: Are more than the 5 R’s involved? Int J Radiat Oncol Biol Phys. 2014; 88: 254-262. doi: 10.1016/j.ijrobp.2013.07.022

Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004; 432: 332-337. doi: 10.1038/nature03096

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006; 6: 392-401. doi: 10.1038/nrc1877

Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a no-vel tumor-promoting cell type. Cell Cycle. 2006; 5: 1597-1601. doi: 10.4161/cc.5.15.3112

Shimoda M, Mellody KT, Orimo A. Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progres-sion. Semin Cell Dev Biol. 2010; 21: 19-25. doi: 10.1016/j.semc-db.2009.10.002

Mishra P, Banerjee D, Ben-Baruch A. Chemokines at the cross-roads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol. 2011; 89: 31-39. doi: 10.1189/jlb.0310182

Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol. 2007; 9: 1392-1400. doi: 10.1038/ncb1658

Arnold KM, Flynn NJ, Raben A, et al. The impact of radiation on the tumor microenvironment: Effect of dose and fractionation schedules. Cancer Growth Metastasis. 2018; 11: 1179064418761639. doi: 10.1177/1179064418761639 Submit your article to this journal | https://openventio.org/submit-manuscript/

Maeda A, Chen Y, Bu J, Mujcic H, Wouters BG, DaCosta RS. In vivo imaging reveals significant tumor vascular dysfunction and increased tumor hypoxia-inducible factor-1α expression in-duced by high single-dose irradiation in a pancreatic tumor mo-del. Int J Radiat Oncol Biol Phys. 2017; 97: 184-194. doi: 10.1016/j. ijrobp.2016.09.005

Deng L, Liang H, Xu M, et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-de-pendent antitumor immunity in immunogenic tumors. Immunity. 2014; 41: 843-852. doi: 10.1016/j.immuni.2014.10.019

Baird JR, Friedman D, Cottam B, et al. Radiotherapy com-bined with novel STING-targeting oligonucleotides results in re-gression of established tumors. Cancer Res. 2016; 76: 50-61. doi: 10.1158/0008-5472.CAN-14-3619

Perry AK, Chen G, Zheng D, Tang H, Cheng G. The host type I interferon response to viral and bacterial infections. Cell Res. 2005; 15: 407-422. doi: 10.1038/sj.cr.7290309

Prakash H, Klug F, Nadella V, Mazumdar V, Schmitz-Winnen-thal H, Umansky L. Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retu-ning tumor-associated macrophages: Lesson from insulinoma. Carcinogenesis. 2016; 37: 301-313. doi: 10.1093/carcin/bgw007

Klug F, Prakash H, Huber PE, et al. Low-dose irradiation pro-grams macrophage differentiation to an INOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell. 2013; 24: 589-602. doi: 10.1016/j.ccr.2013.09.014

Chiang CS, Fu SY, Wang SC, et al. Irradiation promotes an m2 macrophage phenotype in tumor hypoxia. Front Oncol. 2012; 2: 89. doi: 10.3389/fonc.2012.00089

Okubo M, Kioi M, Nakashima H, et al. M2-polarized macro-phages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation. Sci Rep. 2016; 6: 27548. doi: 10.1038/ srep27548

Seifert L, Werba G, Tiwari S, et al. Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tu-mors in mice. Gastroenterology. 2016; 150: 1659.e5-1672.e5. doi: 10.1053/j.gastro.2016.02.070

Kang J, Demaria S, Formenti S. Current clinical trials testing the combination of immunotherapy with radiotherapy. J Immuno-ther Cancer. 2016; 4: 51. doi: 10.1186/s40425-016-0156-7

Berberat PO, Kunzli BM, Gulbinas A, et al. An audit of outco-mes of a series of periampullary carcinomas. Eur J SurgOncol. 2009; 35: 187-191. doi: 10.1016/j.ejso.2008.01.030

Lafaro KJ, Melstrom LG. The paradoxical web of pancreatic cancer tumor microenvironment. Am J Pathol. 2019; 189(1): 44-57. doi: 10.1016/j.ajpath.2018.09.009

Downloads

Published

2019-12-31

How to Cite

Maged Ghaly, MD, Emile Gogineni, DO, & Muhammad W. Saif, MD. (2019). The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. Pancreas, 3(1), 9–14. Retrieved from https://openventio.us/index.php/POJ/article/view/1171

Issue

Vol. 3 No. 1 (2019): Volume 3 Issue 1 2019

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Pancreas (POJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.